Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | ME3 | Q16798 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13724599 | 0.84 | GFER (0.51) | PDK2ME3NOTUMKMT2ARORC | |
| SCHEMBL22854275 | 0.82 | RORC (0.53) | PDK2ME3NOTUMKMT2APOLB | |
| SCHEMBL2561051 | 0.82 | TRIM24 (0.51) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL28292789 | 0.82 | AKR1C3 (0.50) | ME3NOTUMKMT2AALDH1A1MAPT | |
| SCHEMBL16610843 | 0.81 | MAPT (0.66) | PDK2KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7011465 | 0.81 | F10 (0.50) | PDK2RXFP1CYP46A1 | |
| SCHEMBL14167559 | 0.80 | NOTUM (0.57) | ME3NOTUMKMT2APOLBRXFP1 | |
| SCHEMBL14241715 | 0.78 | CYP46A1 (0.50) | PDK2NOTUMRORCSYKALDH1A1 | |
| SCHEMBL2636348 | 0.78 | KDM4E (0.60) | ALDH1A1 | |
| SCHEMBL13733384 | 0.76 | NOTUM (0.57) | PDK2ME3NOTUMSYKRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332700-A1 | NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | MANKIND PHARMA LTD (IN) | 2022-10-20 | — | — | US | disclosed |
| WO-2020261294-A1 | NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | MANKIND PHARMA LTD. (IN) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020261294-A1 | NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | MANKIND PHARMA LTD. (IN) | 2020-12-30 | — | — | WO | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | PDK2 1057/4885ME3 1573/4885NOTUM 3983/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | PDK2 1057/4885ME3 1573/4885NOTUM 3983/4885 |
| US-20220332700-A1 | NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | BAD, BAX, BCL2 | PDK2 1505/4885ME3 2985/4885NOTUM 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.